EXO70 Antibody

What is EXO70 and why is it important to study?

EXO70 (also known as EXOC7) is a critical component of the evolutionarily conserved exocyst complex that regulates the final steps of exocytosis. This multimeric complex consists of eight subunits (Sec3, Sec5, Sec6, Sec8, Sec10, Sec15, Exo70, and Exo84) and is responsible for tethering secretory vesicles to specific docking sites on the plasma membrane prior to fusion . EXO70 is particularly significant because it directly participates in membrane curvature induction and has roles in cell morphogenesis, directional migration, and vesicle trafficking . Its dysfunction has been implicated in several significant diseases, including diabetes and cancer progression, making it an important target for both basic research and therapeutic development .

Which species reactivity should I consider when selecting an EXO70 antibody?

When selecting an EXO70 antibody, consider your experimental model organism. Commercial antibodies are available with validated reactivity against mouse, rat, and human EXO70 . For example, the 70X13F3 monoclonal antibody specifically recognizes the exocyst complex exo70 subunit and is reactive with both mouse and rat samples . Similarly, the D-6 monoclonal antibody (sc-365825) detects EXO70 protein from mouse, rat, and human origins . Always verify the cross-reactivity of your chosen antibody, especially when working with less common model organisms, as the exocyst complex is conserved across multiple species from yeast to mammals .

What applications are EXO70 antibodies suitable for?

EXO70 antibodies can be utilized in multiple research applications:

For optimal results in immunofluorescence microscopy, incubate cells with the primary antibody at 4°C overnight as demonstrated with methanol-fixed neuroendocrine PC12 cells stained with 0.1 μg/ml antibody .

How should I store and handle EXO70 antibodies?

To maintain antibody integrity and performance, store EXO70 antibodies at -20°C in small aliquots to avoid repeated freeze-thaw cycles . Commercially available antibodies typically come in liquid form at concentrations around 200 μg/ml to 1 mg/ml . When shipping or transporting, use cold packs to maintain temperature. Prior to use, thaw aliquots slowly on ice and briefly centrifuge to collect any precipitate. For diluted working solutions, prepare fresh in appropriate buffers with stabilizing proteins (BSA or serum) and consider adding sodium azide (0.02%) for extended storage at 4°C. Always follow manufacturer-specific recommendations for your particular antibody formulation.

How can I optimize EXO70 antibody specificity for studying specific EXO70 isoforms?

EXO70 undergoes alternative splicing, resulting in four distinct isoforms that may have unique regulatory roles in cellular processes . To study specific isoforms:

• Perform epitope mapping to determine if your antibody recognizes epitopes present in all isoforms or is isoform-specific

• Consider using isoform-specific antibodies if commercially available, or generate custom antibodies against unique regions

• Validate specificity using overexpression systems with tagged isoforms and siRNA/shRNA knockdown controls

• Implement pre-adsorption controls with recombinant proteins of specific isoforms

• Use Western blotting to confirm molecular weight differences between isoforms (typically subtle variations)

For researchers investigating isoform-specific functions, combining immunological detection with molecular approaches (such as RT-PCR to identify expression patterns of each isoform) provides more robust results. When using the complete recombinant protein as immunogen (such as the full-length rat brain exo70 subunit), be aware that the resulting antibodies may recognize multiple isoforms .

What methodological considerations are important when studying EXO70's role in membrane curvature induction?

Investigating EXO70's membrane-deforming properties requires specialized approaches:

• In vitro membrane deformation assays: Use fluorescently-labeled giant unilamellar vesicles (GUVs) to visualize membrane invaginations induced by purified EXO70. The Exo70(Δ1–75) truncation mutant and Exo70(K571A/E572A) membrane-binding deficient mutant serve as important controls that exhibit reduced or abolished membrane deformation activity, respectively .

• Oligomerization analysis: Since EXO70-induced membrane curvature depends on protein oligomerization, employ size exclusion chromatography, analytical ultracentrifugation, or dynamic light scattering to assess oligomeric states.

• Correlative microscopy approaches: For cellular studies, combine time-lapse fluorescence microscopy with platinum replica electron microscopy to distinguish between EXO70-induced membrane protrusions and actin-supported structures .

• Membrane binding assays: Assess protein-lipid interactions using liposome sedimentation assays with defined phospholipid compositions to determine binding specificity and strength.

• Molecular dynamics simulations: Complement experimental data with in silico approaches to model EXO70-membrane interactions at the molecular level .

When interpreting results, note that EXO70 can induce membrane protrusions independently of actin in some contexts, with many filopodial protrusions being either empty or containing very few linear actin filaments .

How can I investigate EXO70's role in lysosome secretion at immune synapses?

To study EXO70's function in lysosome tethering and secretion at the immune synapse of B cells:

• TIRF microscopy: Track lysosome dynamics in real-time at the immune synapse using LysoSensor Green labeling. In EXO70-deficient cells, lysosomes display increased mean velocity, longer trajectories, and lower dwelling times at the synaptic membrane compared to control cells .

• Confocal microscopy of the cell-substrate interface: Analyze the distribution of lysosomes labeled with LAMP-1 at the immune synapse. Control B cells show a radial distribution with lysosomes concentrated at the center, while EXO70-silenced cells display disorganized lysosome patterns .

• Genetic manipulation: Use siRNA to silence EXO70 expression and validate with appropriate controls. Additionally, rescue experiments with EXO70 mutants can help identify functional domains required for lysosome tethering.

• Immunoprecipitation: Investigate protein-protein interactions between EXO70 and lysosomal or cytoskeletal components to understand the molecular mechanisms of tethering.

• Functional secretion assays: Measure antigen extraction and presentation capabilities to assess the functional consequences of altered lysosome secretion.

Research indicates that BCR engagement enhances microtubule stability, which triggers the mobilization of EXO70 from the centrosome to the immune synapse, a critical step in establishing stable lysosome docking .

What strategies can I use to investigate EXO70-specific functions within the exocyst complex?

Distinguishing EXO70-specific functions from those of the entire exocyst complex requires specialized approaches:

• Small molecule inhibitors: Utilize Endosidin2 (ES2), which specifically binds to the EXO70 subunit of the exocyst complex, inhibiting exocytosis and endosomal recycling while enhancing vacuolar trafficking. This approach allows for dosage-dependent modulation of exocyst function without affecting other subunits .

• Domain-specific mutations: Generate truncation mutants like the C-terminal truncated EXO70, which confers dominant ES2 resistance and can reveal distinct regulatory roles for different protein domains .

• Subunit-specific knockdown: Compare phenotypes between EXO70 knockdown and knockdown of other exocyst subunits to identify unique versus shared functions.

• Proteomic approaches: Employ BioID or proximity labeling methods to identify proteins that specifically interact with EXO70 but not other exocyst components.

• Live-cell imaging: Use dual-color imaging with differently tagged exocyst subunits to identify potential sub-complexes or sequential recruitment events.

This approach overcomes the limitations of genetic studies in organisms like Arabidopsis thaliana, where mutant lethality or phenotypic severity complicates the investigation of exocyst-related processes .

How can I address non-specific binding when using EXO70 antibodies?

Non-specific binding is a common challenge when working with EXO70 antibodies. Implement these methodological solutions:

• Optimize blocking conditions: Test different blocking agents (BSA, normal serum, casein, commercial blockers) at various concentrations (3-5%) and incubation times (1-2 hours at room temperature or overnight at 4°C).

• Titrate antibody concentration: Perform a dilution series to determine the optimal concentration that maximizes specific signal while minimizing background. Starting ranges for the 70X13F3 antibody are 0.01 μg/ml for Western blotting and 0.1 μg/ml for immunofluorescence .

• Include validation controls:

  • Peptide competition assays using the immunizing antigen

  • EXO70 knockdown/knockout samples as negative controls

  • Recombinant EXO70 protein as a positive control

  • Multiple antibodies targeting different epitopes of EXO70

• Modify washing protocols: Increase washing stringency by adding detergents (0.1-0.3% Triton X-100 or Tween-20) and extending washing times.

• Pre-adsorb antibody: Incubate diluted antibody with tissues or cell lysates from species not expressing the target to remove antibodies that cross-react with conserved epitopes.

When troubleshooting Western blots specifically, ensure you're using 8% SDS-polyacrylamide gels, which are optimal for resolving the 70 kDa EXO70 protein .

What control experiments should I include when studying EXO70 in exocytosis pathways?

To ensure robust and reproducible results when investigating EXO70's role in exocytosis:

• Expression controls:

  • Validate EXO70 knockdown/overexpression efficiency at both mRNA (qRT-PCR) and protein (Western blot) levels

  • Monitor expression levels of other exocyst subunits to detect compensatory changes

• Functional controls:

  • Small molecule inhibition: Use Endosidin2 (ES2) as a tool to specifically target EXO70 function in a dose-dependent manner

  • Rescue experiments: Reintroduce wild-type or mutant EXO70 constructs in knockdown/knockout backgrounds

  • Dominant-negative approaches: Express truncated forms like EXO70(Δ1–75) that disrupt normal function

• Specificity controls:

  • Parallel analysis of other exocyst subunits to distinguish EXO70-specific effects

  • Examination of unrelated secretory pathways to confirm specificity

• Localization controls:

  • Co-localization with established markers of secretory vesicles and plasma membrane domains

  • Compare distribution patterns with other exocyst components

• Cargo-specific controls:

  • Trace multiple secretory cargoes to distinguish general versus cargo-specific effects

  • Include non-exocytic cargo (e.g., endocytic markers) to confirm pathway specificity

These controls help distinguish direct effects of EXO70 manipulation from indirect consequences or adaptive responses.

How can I reconcile contradictory data when studying EXO70 function across different cell types?

Contradictory findings regarding EXO70 function across different cell types are common due to its context-dependent roles. To address these discrepancies:

• Systematic comparison approach:

  • Conduct parallel experiments in multiple cell types under identical conditions

  • Create a standardized experimental framework that accounts for cell-specific parameters

• Isoform expression analysis:

  • Characterize EXO70 isoform expression patterns across different cell types, as alternative splicing generates four distinct isoforms with potentially different functions

  • Use isoform-specific detection methods where possible

• Interaction networks mapping:

  • Identify cell-type-specific interaction partners of EXO70 using proteomics approaches

  • Determine whether differences in function correlate with differences in protein-protein interactions

• Consider physiological context:

  • In polarized cells (like neurons or epithelial cells), EXO70 may function in directional secretion

  • In immune cells, EXO70 regulates specialized secretory events at immunological synapses

  • In migrating cells, EXO70 contributes to membrane protrusion formation

• Technical validation:

  • Ensure antibodies recognize the same epitopes across species and cell types

  • Validate knockdown/overexpression systems in each cell type studied

By systematically addressing these factors, researchers can determine whether contradictory findings reflect genuine biological differences or technical limitations.

How can EXO70 antibodies be utilized to study its role in disease mechanisms?

EXO70 dysfunction has been implicated in several significant diseases, including diabetes and cancer progression . Researchers can leverage EXO70 antibodies to investigate disease mechanisms through:

• Clinical sample analysis:

  • Compare EXO70 expression, localization, and post-translational modifications in patient-derived samples versus healthy controls

  • Perform tissue microarray analysis using immunohistochemistry in cancer progression studies

• Disease model systems:

  • Track EXO70 dynamics in cellular and animal models of diabetes, cancer, and neurological disorders

  • Correlate changes in EXO70 localization or expression with disease progression markers

• Therapeutic target validation:

  • Use antibodies to validate EXO70 as a potential drug target by confirming its involvement in pathological processes

  • Screen for compounds that alter EXO70 function similar to the small molecule Endosidin2 (ES2)

• Biomarker development:

  • Evaluate EXO70 as a potential disease biomarker through quantitative immunoassays

  • Investigate correlations between EXO70 levels/modifications and disease state or treatment response

• Mechanistic studies:

  • Use proximity labeling combined with antibody-based detection to identify disease-specific interaction partners

  • Investigate how disease-associated mutations affect EXO70 function using structure-function analyses

These approaches can provide new insights into how altered EXO70 function contributes to disease pathogenesis and potentially identify new therapeutic strategies.

What methodologies are emerging for studying post-translational modifications of EXO70?

Investigating post-translational modifications (PTMs) of EXO70 is an emerging research area that can reveal regulatory mechanisms of exocyst complex function:

• Modification-specific antibodies:

  • Develop and validate antibodies that specifically recognize phosphorylated, ubiquitinated, or other modified forms of EXO70

  • Use these tools in Western blotting and immunofluorescence to detect spatial and temporal regulation of modifications

• Mass spectrometry approaches:

  • Employ immunoprecipitation with anti-EXO70 antibodies followed by mass spectrometry to identify PTM sites

  • Utilize quantitative proteomics to compare modification profiles under different cellular conditions

• Site-specific mutants:

  • Generate EXO70 mutants with modified PTM sites (phosphomimetic or non-phosphorylatable mutations)

  • Express these in EXO70-depleted backgrounds to assess functional consequences

• Live-cell imaging of modification dynamics:

  • Combine antibody-based detection with live cell imaging to track modifications during dynamic cellular processes

  • Utilize FRET-based biosensors to monitor modification events in real-time

• Enzymatic regulation:

  • Identify and manipulate the enzymes responsible for adding or removing PTMs from EXO70

  • Use pharmacological inhibitors or genetic approaches to modulate these enzymes

These methodologies will help elucidate how modifications like phosphorylation affect EXO70's membrane binding, protein interactions, and role in exocytosis regulation.

What are the current limitations of EXO70 antibodies and how might they be addressed in future research?

Current EXO70 antibody technology faces several limitations that future research may overcome:

• Isoform specificity: Most available antibodies cannot distinguish between the four EXO70 isoforms resulting from alternative splicing . Future development of highly specific monoclonal antibodies raised against isoform-unique epitopes will enable more precise characterization of isoform-specific functions.

• Species cross-reactivity: While current antibodies recognize EXO70 in common model organisms (mouse, rat, human) , expanded validation across diverse species would facilitate evolutionary studies of exocyst function.

• PTM detection: Limited availability of modification-specific antibodies restricts our understanding of EXO70 regulation. Development of antibodies that recognize specific phosphorylation, ubiquitination, or SUMOylation states would advance regulatory studies.

• Conformational states: Current antibodies cannot distinguish between active/inactive or complex-bound/free states of EXO70. Advanced antibody engineering to recognize specific conformational states could reveal dynamic regulation mechanisms.

• Live-cell applications: Most applications require fixed samples. Development of intrabodies or nanobodies compatible with live-cell imaging would enable real-time tracking of endogenous EXO70 dynamics.

Future antibody technologies, including recombinant antibody fragments, aptamer-based detection, and synthetic binding proteins, may overcome these limitations to provide more precise tools for EXO70 research.

How can integrating EXO70 antibody-based approaches with other technologies advance our understanding of exocyst function?

Advancing exocyst research requires combining antibody-based approaches with complementary technologies:

• Multiplexed imaging:

  • Integrate antibody detection with expansion microscopy or super-resolution techniques to visualize nanoscale organization of exocyst components

  • Combine with electron microscopy for ultrastructural analysis of EXO70-mediated membrane remodeling

• Single-cell analysis:

  • Couple antibody-based detection with single-cell transcriptomics to correlate EXO70 protein levels with gene expression patterns

  • Implement CyTOF or imaging mass cytometry for high-dimensional phenotyping of exocyst status in heterogeneous populations

• CRISPR-based approaches:

  • Generate endogenously tagged EXO70 for live imaging combined with antibody validation

  • Create conditional knockouts for temporal control of EXO70 depletion

  • Engineer domain-specific mutations to dissect structure-function relationships

• Pharmacological tools:

  • Expand upon the Endosidin2 (ES2) approach to develop additional small molecules targeting different EXO70 domains

  • Create chemical-genetic systems for rapid, reversible control of EXO70 function

• Computational modeling:

  • Integrate antibody-validated localization data with molecular dynamics simulations to model EXO70-membrane interactions

  • Develop predictive models of exocyst assembly and function based on experimentally determined constraints

The combination of these approaches with traditional antibody-based methods will provide a more complete understanding of exocyst complex dynamics and function across different biological contexts.